This study looked at the benefit of using the PARP inhibitor niraparib to treat metastatic castration-resistant prostate cancer (mCRPC). Participants included those with an inherited or tumor mutation in BRCA1 or BRCA2 or an inherited or tumor mutation in another gene that affects DNA repair. Participants with an inherited or tumor mutation in BRCA1 or BRCA2 had better survival compared to those without a BRCA mutation. Side effects from niraparib were common, and consistent with previous reports for PARP inhibitors. (posted 9/6/2022)
Este artículo está disponible en español.
The following studies are looking at PARP inhibitors and similar agents for treating people with advanced prostate cancer.
Other clinical trials for people with prostate cancer can be found here.
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.